These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20854761)

  • 41. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
    Wild C; Nachtnebel A
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
    Ling K; Qin H; Feng Y; Che H; Ding J; Li W
    Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale].
    Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J
    Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical added value of drugs: An empirical survey of French transparency committee opinions.
    Detournay B; Borel T; Trancart M; Emery C; Coudray-Omnès C;
    Therapie; 2021; 76(6):639-645. PubMed ID: 30470477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
    Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
    Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The transparency commission: evaluation and re-evaluation].
    Bergmann JF
    Presse Med; 2001 May 26-Jun 2; 30(19):941-6. PubMed ID: 11433724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
    Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
    J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer.
    Mohseninejad L; van Gils C; Uyl-de Groot CA; Buskens E; Feenstra T
    Value Health; 2015 Jan; 18(1):84-90. PubMed ID: 25595238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
    Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
    Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies.
    Stevens W; Philipson T; Wu Y; Chen C; Lakdawalla D
    Forum Health Econ Policy; 2014 Jan; 17(1):21-52. PubMed ID: 31419878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology?
    Pavlovic M; Garnier J; Durand-Zaleski I; ; Bilbault P; Gaudin AF; Le Jeunne C; Lalaude O; Roze S; de Sahb R; Sapède C
    Therapie; 2016 Dec; 71(6):625-632. PubMed ID: 27639631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
    Lux MP; Ciani O; Dunlop WCN; Ferris A; Friedlander M
    Cancer Manag Res; 2021; 13():8457-8471. PubMed ID: 34795526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
    Pham FY; Jacquet E; Taleb A; Monard A; Kerouani-Lafaye G; Turcry F; Brunel L; Grudé F; Yoldjian I; Sainte-Marie I; Boudali L; Blay JY; Albin N
    Int J Cancer; 2022 Oct; 151(8):1345-1354. PubMed ID: 35603979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early market access of cancer drugs in the EU.
    Martinalbo J; Bowen D; Camarero J; Chapelin M; Démolis P; Foggi P; Jonsson B; Llinares J; Moreau A; O'Connor D; Oliveira J; Vamvakas S; Pignatti F
    Ann Oncol; 2016 Jan; 27(1):96-105. PubMed ID: 26487583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How to best define target populations of medicines in view of their coverage by the national health insurance scheme?
    Hamers FF; Massol J; Maillère P;
    Therapie; 2010; 65(4):341-5, 335-9. PubMed ID: 20854757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.
    Chouaid C; Borget I; Braun E; Bazil ML; Schaetz D; Rémuzat C; Toumi M
    Target Oncol; 2016 Aug; 11(4):515-34. PubMed ID: 26830301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relative Added Value: What are the Tools to Evalue it?
    Jeunne CL; Woronoff-Lemsi MC; David N; Sahb Rd;
    Therapie; 2008; 63(2):113-7. PubMed ID: 27393729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Keynote comment: reimbursement for molecularly targeted anticancer agents.
    Tirelli U; de Castro G; Awada A
    Lancet Oncol; 2006 Jan; 7(1):2-3. PubMed ID: 16389172
    [No Abstract]   [Full Text] [Related]  

  • 60. Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.
    Robinson AG; Booth CM; Eisenhauer EA
    Eur J Cancer; 2014 Sep; 50(13):2298-302. PubMed ID: 24930623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.